Rook Epicardial Access Device Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03427333|
Recruitment Status : Recruiting
First Posted : February 9, 2018
Last Update Posted : February 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Ventricular Tachycardia Arrythmia||Device: The Rook® Epicardial Access Kit||Not Applicable|
This is a first-in-human, prospective, non-randomized, single arm study to confirm the efficacy and safety of the Talon Surgical Rook® Epicardial Access Kit to achieve guidewire access to the pericardial space. Patients who are clinically indicated to undergo a procedure that requires percutaneous access to the normal, non-distended, pericardial space will be considered for enrollment into this clinical trial. This may include, but is not limited to, patients who require pericardial access for epicardial ablation procedure or for pigtail catheter placement during pacemaker lead extraction. The study population will consist of both male and female patients of at least 18 years of age. In addition, eligible patients will have a life expectancy of at least 6 months based on a physician's assessment of the patient's medical condition. Patients who meet all inclusion and non-exclusion criteria, who are willing to comply with study follow-up requirements, and for whom documented informed consent is obtained, will be eligible for enrollment in the study. Enrollment occurs when the device enters the body.
Patients who undergo attempted use of a study device (patient leaves procedure room with device having entered the body at some point during the procedure), regardless of whether or not the device was successfully used for pericardial access, will be followed through discharge or up to 4 days post procedure, whichever comes first.
The study will include a minimum of 10 patients and up to 30 patients with the study devices used for pericardial access. Multiple study site may be utilized. The duration of participation for each enrolled patient who utilizes a study device for pericardial access will be through hospital discharge, or up to 4 days post procedure, whichever comes first.
A study physician will utilize the Rook® Epicardial Access Kit to gain access to the pericardial space. The physician will follow the patient through hospital discharge, or up to 4 days post procedure, whichever comes first, for adverse events, and other device or procedure related observations. The study coordinator or designated study personnel at the Principle Investigator's office will be responsible for collecting data from the procedure and hospital stay which will be necessary for completion of case report form for the index procedure and subsequent follow up.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Intervention Model: Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Rook Epicardial Access Device Study|
|Actual Study Start Date :||January 18, 2018|
|Estimated Primary Completion Date :||May 1, 2018|
|Estimated Study Completion Date :||June 1, 2018|
Experimental: The Rook® Epicardial Access Kit
The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.
Device: The Rook® Epicardial Access Kit
Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.
- Percentage of Patient in Whom Successful Pericardial Access was Achieved Through Use of the Rook Epicardial Access Kit [ Time Frame: At time of intervention. ]Standard x-ray (fluoroscopy) will be used to confirm that the Talon Surgical Rook® Epicardial Access Kit facilitated successful placement of a guidewireinto the pericardial space. Successful placement of the guidewire into the pericardial space will be noted for each patient. The percentage of patients in whom pericardial access was successful will be reported.
- Number of Participants with Device or Procedure Related Adverse Events as Adjudicated by the Clinical Event Committee [ Time Frame: Up to 4 days post procedure. ]Occurrence of CEC-adjudicated device or procedure related adverse events through hospital discharge or up to 4 days post procedure, whichever comes first, will be documented for each patient. The total number of patients with adverse events and the number of each adverse events will be reported. This outcome will also be reported as a percentage.
- Speed of Access [ Time Frame: At time of intervention ]Time from skin incision to confirmed guidewire access to the pericardial space.
- Ease of Use [ Time Frame: At time of intervention. ]Evaluation of the study procedure compared to the standard of care pericardial access procedure with a Tuohy Needle by clinician survey.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03427333
|Contact: Nathaniel Youngfirstname.lastname@example.org|
|Contact: Jay Museemail@example.com|
|Na Homolce Hospital||Recruiting|
|Contact: Katerina Mzourkova +420 606 532 420 firstname.lastname@example.org|
|Principal Investigator: Petr Neuzil, MD PhD|
|Principal Investigator: Vivek Reddy, MD|